Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.

LATEST PRESS RELEASES

10 March 2021

Stayble appoints Professor Hans Jörg Meisel as a member of the scientific advisory board

Stayble Therapeutics today announced that the company’s scientific advisory board gains new expertise through the appointment of Professor Hans Jörg Meisel, Berlin, Germany. Prof. Meisel adds furth...

04 March 2021 Regulatory

Last day of trading in BTA

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8 March 2021 and stop day will be on 10 Marc...

FINANCIAL CALENDAR

Interim report Q1 2021
17May2021
Interim report Q2 2021
16August2021
Interim report Q3 2021
18November2021